MagnetisMM-7 : Étude de phase 3 à répartition aléatoire et à 2 groupes visant à évaluer l’elranatamab (PF-06863135) comparativement au lénalidomide chez des patients atteints d’un myélome multiple nouvellement diagnostiqué après avoir reçu une greffe autologue de cellules souches.
Type de maladie :
Traitement :
Population :
Première ligne
Thérapie ciblée
Adultes
Critères d'inclusion
Critères d'exclusion
Hopitaux participants
Contact
Diagnosis of MM as defined according to IMWG criteria (Rajkumar, 2014) with measurable disease at diagnosis
History of induction therapy for newly diagnosed MM, followed by high dose therapy and autologous stem cell transplant. Randomization must occur within 120 days from the stem cell transplant. For participants who receive consolidation therapy after ASCT, randomization must occur within 60 days of consolidation and within 7 months from ASCT.
Partial Response or better according to IMWG criteria at the time of randomization
Must have an archival bone marrow aspirate sample(s) to identify the dominant malignant (index) clone by central laboratory NGS test (ClonoSEQ assay) that is used to track MRD status. This sample should preferably be collected before induction treatment (eg, at diagnosis) or before transplant.
ECOG performance status ≤1
Resolved acute effects of any prior therapy to baseline severity or CTCAE Grade ≤ 1
Not pregnant and willing to use contraception
Diagnosis of MM as defined according to IMWG criteria (Rajkumar, 2014) with measurable disease at diagnosis
History of induction therapy for newly diagnosed MM, followed by high dose therapy and autologous stem cell transplant. Randomization must occur within 120 days from the stem cell transplant. For participants who receive consolidation therapy after ASCT, randomization must occur within 60 days of consolidation and within 7 months from ASCT.
Partial Response or better according to IMWG criteria at the time of randomization
Must have an archival bone marrow aspirate sample(s) to identify the dominant malignant (index) clone by central laboratory NGS test (ClonoSEQ assay) that is used to track MRD status. This sample should preferably be collected before induction treatment (eg, at diagnosis) or before transplant.
ECOG performance status ≤1
Resolved acute effects of any prior therapy to baseline severity or CTCAE Grade ≤ 1
Not pregnant and willing to use contraception
CIUSSS de l’Est-de-l’Ile-de-Montreal (HMR)
McGill
CIUSSS NIM/Hôpital du Sacré-Coeur de Montréal
CIUSSS de l’Est-de-l’Ile-de-Montreal (HMR)
Nom de chercheur / email – Dr Richard LeBlanc / richard.leblanc.med2@ssss.gouv.qc.ca